Highlights
NASDAQ: ALXN       Alexion Pharm Inc
Last Price Today's Change   Day's Range   Trading Volume
155.69   -4.08 (2.55%)  155.28 - 162.60  3,729,500

Overview

 
Avg Volume (4 weeks):3,032,531
4 Weeks Range:154.23 - 162.60
4 Weeks Price Volatility (%):
17.44%
52 Weeks Range:72.67 - 162.60
52 Weeks Price Volatility (%):
92.32%
Average Price Target: 208.00
Price Target Upside/Downside: +52.31

Headlines



No recent Headlines for this stock.


Business Background

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  Be the first to like this.
 


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
 
 

2563  6639  404  79 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 NAKD 1.38+0.988 
 AMC 19.90-0.44 
 NOK 6.55+1.56 
 SNDL 0.60+0.10 
 CTRM 0.532+0.182 
 BB 25.10+4.85 
 EXPR 9.55+1.62 
 GNUS 3.06+1.43 
 UVXY 13.87+2.47 
 AAL 16.56+1.14 

TOP ARTICLES

1. Daily Futures Trading Strategy 27 January 2021 Where Futures Lies
2. CryptoNews of the Week CryptoNews
3. Equities Slipped While Waiting For Feds State of The Markets
4. Daily Futures Trading Strategy 26 January 2021 Where Futures Lies
5. Markets Mixed Amid Stimulus Hope State of The Markets